Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma

European Journal of Cancer

Volumn 34, Issue SUPPL. 3, 1998, Pages 22-26

  Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant therapy; Ganglioside; Interferon; Melanoma; Trials; Vaccine

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CARMUSTINE; DACARBAZINE; GAMMA INTERFERON; GANGLIOSIDE GM2; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LEVAMISOLE; LOMUSTINE; MELANOMA VACCINE; QS 21;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MELANOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0031710142     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(97)10160-5     Document Type: Conference Paper

References (47)

1. Slingluff CL, Dodge RK, Stanley WE, Seigler BF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992, 70, 1917-1927.
2. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985, 13, 756-760.
3. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gyn Obst 1988, 166, 497-502.
4. Rogers GS, Kopf AW, Rigel DS, Friedman RJ, Levenstein M, Bart RS. Hazard rate analysis in stage I malignant melanoma. Arch Dermatol 1986, 122, 999-1002.
5. Schraffordt Koops H, Vaglini M, Kroon BBR, et al. Value of prophylactic isolated limb perfusion (ILP) for stage I high risk malignant melanoma: a randomised phase III trial (abstract). Melanoma Res 1997, 7(Suppl. 1), S34.
6. Cascinelli N, Vaglini M, Nava M, et al. Prognosis of skin melanoma with regional node metastases (stage II). J Surg Oncol 1984, 25, 240-247.
7. Callery C, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surgery 1982, 196, 69-75.
8. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke Ph. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC PROTOCOL 18781). Eur J Cancer 1993, 29A, 1237-1242.
9. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 1981, 61, 1267-1277.
10. Hill GJ II, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma. Cancer 1981, 47, 2556-2562.
11. Lejeune FJ, Macher E, Kleeberg UR, et al. An assessment of DTIC versus levamisole and placebo in the treatment of high risk stage I patients after removal of a primary melanoma of the skin, a phase III adjuvant study. EORTC PROTOCOL 18761. Eur J Cancer Oral Oncol 1988, 24, 881-890.
12. Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987, 10, 325-328.
13. Pinsky CM, Oettgen HF. Surgical adjuvant for malignant melanoma. Surg Clin North Am 1981, 61, 1259-1266.
14. Quirt IC, DeBoer G, Kersey PA, et al. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983, 128, 929-936.
15. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Troup. J Clin Oncol 1991, 9, 729-735.
16. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991, 9, 736-740.
17. Tranum BL, Dixon D, Quagliana J, et al. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 1987, 71, 643-644.
18. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982, 307, 913-916.
19. Balch CM, Smalley RV, Bartolucci AA, et al. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer 1982, 49, 1079-1084.
20. Karakousis CP, Didolkar MS, Lopez R, et al. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treat Rep 1979, 63, 1739-1743.
21. Thatcher N, Mene A, Banerjee SS, et al. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma. Br J Surg 1986, 73, 111-115.
22. Morton DL. Adjuvant immunotherapy, of malignant melanoma: status of clinical trials at UCLA. Im J Immunother 1986, 2, 31-36.
23. Morton DL, Holmes EC, Eilber FR, et al. Adjuvant immunotherapy: results of a randomized trial in patients with lymph node metastases. In Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York, Elsevier, 1982, 245-249.
24. Terry WD, Modes RJ, Rosenberg SA, et al. Treatment of stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: preliminary analysis of a prospective randomized trial. In Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York, Elsevier, 1982, 252-257.
25. Hersey P, Coates P, Tyndall L. Is adjuvant therapy worthwhile (abstract)? Melanoma Res 1997, 7(Suppl.), S22-S23.
26. Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995, 75, 34-42.
27. Meyskens FL, Liu PY, Tuthill RJ, et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group Study. J Clin Oncol 1994, 12, 2060-2065.
28. Meyskens FL, Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon-gamma versus observation in high risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst 1995, 87, 1710-1713.
29. Pehamberger H, Soyer P, Steiner A, et al. Adjuvant interferon alpha-2a treatment in resected primary cutaneous melanoma (abstract). Melanoma Res 1997, 7(Suppl. 1), S31.
30. Grob JJ, Dreno B, Chastang C, et al. Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (abstract). Proc Am Soc Clin Oncol 1996, 15, 437.
31. Grob JJ, Dreno B, Delaunay M, et al. Long term results of and adjuvant therapy with low doses IFN-α2A in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases (abstract). Melanoma Res 1997, 7(Suppl. 1), S33.
32. Hauschild A, Burg G, Dummer R. Prospective randomized multicenter trial on the outpatient use of subcutaneous interleukin 2 and interferon α2b in high risk melanoma patients (abstract). Melanoma Res 1997, 7(Suppl. 1), S115.
33. Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc NatlAcad Sci USA 1987, 84, 2911-2915.
34. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989, 49, 7045-7050.
35. Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994, 12, 1036-1044.
36. Carubia JM, Yu RK, Macala LJ, et al. Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Comm 1984, 120, 500.
37. Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 1993, 53, 566-573.
38. Jones PC, Sze LL, Liu PY, et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981, 66, 249-254.
39. Helling F, Zhang A, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995, 55, 2783-2788.
40. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon-α2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14, 7-17.
41. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1996, 14, 2666-2673.
42. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997, 15, 2351-2358.
43. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomised surgical adjuvant clinical trial or recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995, 13, 2776-2783.
44. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme (letter). Lancet 1994, 343, 913.
45. Cascinelli N. Evaluation of efficacy of adjuvant rIFNα 2A in regional node metastases (abstract). Proc Am Soc Clin Oncol 1995, 14, 410.
46. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992, 216, 463-482.
47. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990, 8, 856-869.